Alto Neuroscience (NYSE:ANRO) Hits New 52-Week High - Here's What Happened

Key Points

• New 52-week high: Alto Neuroscience (ANRO) traded as high as $25.90 and last at $25.62 on volume of ~787,220 shares, a rise of about 12.5% from the prior close.
• Analyst sentiment is a consensus "Moderate Buy" (six Buys, one Hold, one Sell) with a consensus price target of $35.14 and individual targets ranging roughly from $21 to $38.
• The company has a market cap of ~$818.5M and reported Q1 EPS of -$0.45, beating estimates of -$0.56; it shows strong liquidity (current and quick ratios 15.69), low debt-to-equity (0.12), and recent institutional buying activity.

Alto Neuroscience, Inc. (NYSE:ANRO - Get Free Report) shares reached a new 52-week high during trading on Tuesday . The company traded as high as $25.90 and last traded at $25.6210, with a volume of 787220 shares trading hands. The stock had previously closed at $22.78.

Wall Street Analyst Weigh In

ANRO has been the subject of a number of research analyst reports. Robert W. Baird lowered their target price on Alto Neuroscience from $41.00 to $38.00 and set an "outperform" rating for the company in a research note on Thursday, April 2nd. Chardan Capital restated a "buy" rating and issued a $30.00 target price on shares of Alto Neuroscience in a research note on Thursday, April 2nd. Wedbush lowered their target price on Alto Neuroscience from $22.00 to $21.00 and set a "neutral" rating for the company in a research note on Thursday, April 2nd. Weiss Ratings restated a "sell (e+)" rating on shares of Alto Neuroscience in a research note on Monday, December 29th. Finally, BTIG Research raised their target price on Alto Neuroscience from $27.00 to $28.00 and gave the company a "buy" rating in a research note on Tuesday, February 17th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Alto Neuroscience currently has a consensus rating of "Moderate Buy" and a consensus price target of $35.14.

Alto Neuroscience Stock Up 12.5%

The stock has a 50 day simple moving average of $20.10 and a 200-day simple moving average of $15.75. The firm has a market cap of $818.49 million, a PE ratio of -11.75 and a beta of 2.01. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.69.

Alto Neuroscience (NYSE:ANRO - Get Free Report) last announced its quarterly earnings data on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.56) by $0.11. Sell-side analysts predict that Alto Neuroscience, Inc. will post -2.54 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ANRO. Torren Management LLC bought a new stake in shares of Alto Neuroscience in the 4th quarter worth $62,000. Balyasny Asset Management L.P. bought a new stake in shares of Alto Neuroscience in the 4th quarter worth $198,000. OMERS ADMINISTRATION Corp bought a new stake in shares of Alto Neuroscience in the 4th quarter worth $221,000. Vanguard Personalized Indexing Management LLC increased its holdings in shares of Alto Neuroscience by 13.7% in the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 17,045 shares of the company's stock worth $69,000 after purchasing an additional 2,055 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. bought a new stake in shares of Alto Neuroscience in the 4th quarter worth $304,000.

About Alto Neuroscience

Alto Neuroscience NYSE: ANRO is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto's proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.